The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Diet Supplement Tied to Hepatitis

Back to News Homepage

Next

43 of 44 Patients Achieved Sustained Virologic Response (SVR)

Key Findings About HCV Genotype 3

Print this page

Learn about the clinical data which suggests that interferon-free regimens containing Gilead’s Sovaldi (sofosbuvir) and Bristol-Myers Squibb’s NS5A inhibitor daclatasvir have advantages over currently available regimens for HCV genotype-3 infections.

Regimens Containing Gilead’s Sovaldi Have Major Advantages over Other Therapies for Hepatitis C Virus Genotype-3

Gastroenterologists Would Prescribe Sovaldi plus Daclatasvir plus Ribavirin to 60 Percent of Their Genotype-3 Patients, According to Findings from Decision Resources Group

PR Newswire

BURLINGTON, Mass., April 1, 2014 /PRNewswire/ — Decision Resources Group finds that surveyed gastroenterologists in the United States and Europe agree that the percentage of hepatitis C virus (HCV) genotype-3 infected patients with cirrhosis of the liver achieving a sustained virologic response (SVR) is one of the attributes that most influences their prescribing decisions. Clinical data and interviewed experts indicate that interferon-free regimens containing Gilead’s Sovaldi (sofosbuvir) and Bristol-Myers Squibb’s NS5A inhibitor daclatasvir have convenience and efficacy advantages over currently available regimens for HCV genotype-3 infections. However, competition from other NS5A inhibitors, such as Gilead’s GS-5816, may constrain uptake of daclatasvir.

Continue reading this entire article:
http://www.digitaljournal.com/pr/1825244

1 Comment
Share
Share

Previous

Diet Supplement Tied to Hepatitis

Back to News Homepage

Next

43 of 44 Patients Achieved Sustained Virologic Response (SVR)

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.